## J5

5lr2643 CF HB 1243

## By: Senator Lam

Introduced and read first time: January 28, 2025 Assigned to: Finance

Committee Report: Favorable with amendments Senate action: Adopted Read second time: March 10, 2025

CHAPTER \_\_\_\_\_

1 AN ACT concerning

### $\mathbf{2}$

## Health Insurance - Coverage for Specialty Drugs

- FOR the purpose of prohibiting certain insurers, nonprofit health service plans, and health maintenance organizations from excluding coverage for certain specialty drugs that are administered or dispensed by a provider that meets certain criteria; requiring the reimbursement rate for certain specialty drugs to meet certain criteria; and generally relating to health insurance coverage for specialty drugs.
- 8 BY repealing and reenacting, without amendments,
- 9 Article Insurance
- 10 Section 15-847(a)(1) and (5)
- 11 Annotated Code of Maryland
- 12 (2017 Replacement Volume and 2024 Supplement)
- 13 BY repealing and reenacting, with amendments,
- 14 Article Insurance
- 15 Section 15–847(d), 15–1611.1, and 15–1612
- 16 Annotated Code of Maryland
- 17 (2017 Replacement Volume and 2024 Supplement)
- 18 BY adding to
- 19 Article Insurance
- 20 Section <u>15–847(h) and</u> 15–847.2
- 21 Annotated Code of Maryland
- 22 (2017 Replacement Volume and 2024 Supplement)

### EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.

[Brackets] indicate matter deleted from existing law.

Underlining indicates amendments to bill.

Strike out indicates matter stricken from the bill by amendment or deleted from the law by amendment.



# SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND, That the Laws of Maryland read as follows: Article – Insurance 15 - 847.In this section the following words have the meanings indicated. (a) (1)(5)(i) "Specialty drug" means a prescription drug that: 1. is prescribed for an individual with a complex or chronic medical condition or a rare medical condition; 2. costs \$600 or more for up to a 30-day supply; 3. is not typically stocked at retail pharmacies; and 4. A. requires a difficult or unusual process of delivery to the patient in the preparation, handling, storage, inventory, or distribution of the drug; or requires enhanced patient education, management, or В. support, beyond those required for traditional dispensing, before or after administration of the drug.

16 (ii) "Specialty drug" does not include a prescription drug prescribed
17 to treat diabetes, HIV, or AIDS.

(d) Subject to <u>SUBSECTION (H) OF THIS SECTION AND</u> § 15–805 of this subtitle
[and], notwithstanding § 15–806 of this subtitle, [nothing in] AND EXCEPT AS PROVIDED
IN § 15–847.2 OF THIS SUBTITLE, this article or regulations adopted under this article
[precludes] DO NOT PRECLUDE an entity subject to this section from requiring a covered
specialty drug to be obtained through:

(1) a designated pharmacy or other source authorized under the Health
 Occupations Article to dispense or administer prescription drugs; or

(2) a pharmacy participating in the entity's provider network, if the entity
 26 determines that the pharmacy:

- 27 (i) meets the entity's performance standards; and
- 28 (ii) accepts the entity's network reimbursement rates.

 $\frac{1}{2}$ 

3

4

 $\mathbf{5}$ 

6

7

8

9

10

11

12

13

14

15

1(H)THIS SECTION MAY NOT BE CONSTRUED TO SUPERSEDE THE AUTHORITY2OF THE HEALTH SERVICES COST REVIEW COMMISSION TO SET RATES FOR3SPECIALTY DRUGS ADMINISTERED TO PATIENTS IN A SETTING REGULATED BY THE4HEALTH SERVICES COST REVIEW COMMISSION.

5 **15-847.2**.

6 (A) IN THIS SECTION, "SPECIALTY DRUG" HAS THE MEANING STATED IN § 7 15–847 OF THIS SUBTITLE.

8 (B) (1) THIS SECTION APPLIES TO:

9 (I) INSURERS AND NONPROFIT HEALTH SERVICE PLANS THAT 10 PROVIDE COVERAGE FOR PRESCRIPTION DRUGS UNDER INDIVIDUAL, GROUP, OR 11 BLANKET HEALTH INSURANCE POLICIES OR CONTRACTS THAT ARE ISSUED OR 12 DELIVERED IN THE STATE; AND

(II) HEALTH MAINTENANCE ORGANIZATIONS THAT PROVIDE
 COVERAGE FOR PRESCRIPTION DRUGS UNDER INDIVIDUAL OR GROUP CONTRACTS
 THAT ARE ISSUED OR DELIVERED IN THE STATE.

16 (2) AN INSURER, A NONPROFIT HEALTH SERVICE PLAN, OR A HEALTH 17 MAINTENANCE ORGANIZATION THAT PROVIDES COVERAGE FOR PRESCRIPTION 18 DRUGS THROUGH A PHARMACY BENEFITS MANAGER IS SUBJECT TO THE 19 REQUIREMENTS OF THIS SECTION.

20 (C) AN ENTITY SUBJECT TO THIS SECTION MAY NOT EXCLUDE COVERAGE 21 FOR A COVERED SPECIALTY DRUG ADMINISTERED OR DISPENSED BY A PROVIDER 22 UNDER § 12–102 OF THE HEALTH OCCUPATIONS ARTICLE IF THE ENTITY 23 DETERMINES THAT:

24(1) THE PROVIDER THAT ADMINISTERS OR DISPENSES THE COVERED25SPECIALTY DRUG:

26 (I) IS AN IN–NETWORK PROVIDER OF COVERED MEDICAL 27 ONCOLOGY SERVICES; AND

28 (II) COMPLIES WITH STATE REGULATIONS FOR THE 29 ADMINISTERING AND DISPENSING OF SPECIALTY DRUGS; AND

30 (2) THE COVERED SPECIALTY DRUG IS:

31 (I) <del>INFUSED,</del> AUTO–INJECTED, OR AN ORAL TARGETED 32 IMMUNE MODULATOR; OR

4 **SENATE BILL 975 (II)** AN ORAL MEDICATION THAT: 1. **REQUIRES COMPLEX DOSING BASED ON CLINICAL PRESENTATION; OR** 2. IS USED CONCOMITANTLY WITH OTHER INFUSION OR **RADIATION THERAPIES. (D)** (1) THE SUBJECT TO SUBSECTION (F) OF THIS SECTION, THE REIMBURSEMENT RATE FOR SPECIALTY DRUGS COVERED UNDER THIS SECTION SHALL BE: **(I)** AGREED TO BY THE COVERED, IN-NETWORK PROVIDER AND <del>(1)</del> THE ENTITY SUBJECT TO THIS SECTION; AND <del>(2)</del> **(II)** BILLED AT A NONHOSPITAL LEVEL OF CARE OR PLACE OF SERVICE. (2) UNLESS OTHERWISE AGREED TO BY THE COVERED, IN-NETWORK PROVIDER AND THE ENTITY SUBJECT TO THIS SECTION, THE REIMBURSEMENT RATE FOR SPECIALTY DRUGS COVERED UNDER THIS SECTION MAY NOT EXCEED THE RATE APPLICABLE TO A DESIGNATED SPECIALTY PHARMACY FOR DISPENSING THE **COVERED SPECIALTY DRUGS.** 

18 (E) THIS SECTION DOES NOT PROHIBIT AN ENTITY SUBJECT TO THIS 19 SECTION FROM REFUSING TO AUTHORIZE OR APPROVE OR FROM DENYING 20 COVERAGE FOR A COVERED SPECIALTY DRUG ADMINISTERED OR DISPENSED BY A 21 PROVIDER IF ADMINISTERING OR DISPENSING THE DRUG FAILS TO SATISFY 22 MEDICAL NECESSITY CRITERIA.

23(F)THIS SECTION MAY NOT BE CONSTRUED TO SUPERSEDE THE AUTHORITY24OF THE HEALTH SERVICES COST REVIEW COMMISSION TO SET RATES FOR25SPECIALTY DRUGS ADMINISTERED TO PATIENTS IN A SETTING REGULATED BY THE26HEALTH SERVICES COST REVIEW COMMISSION.

27 15–1611.1.

1

 $\mathbf{2}$ 

3

4

5

6

7

8

9

10

11

12

13

14 15

16

17

(a) This section applies only to a pharmacy benefits manager that providespharmacy benefits management services on behalf of a carrier.

30 (b) Except as provided in subsection (c) of this section, a pharmacy benefits 31 manager may not require that a beneficiary use a specific pharmacy or entity to fill a 32 prescription if:

1 (1) the pharmacy benefits manager or a corporate affiliate of the pharmacy 2 benefits manager has an ownership interest in the pharmacy or entity; or

3 (2) the pharmacy or entity has an ownership interest in the pharmacy 4 benefits manager or a corporate affiliate of the pharmacy benefits manager.

5 (c) [A] EXCEPT AS PROVIDED IN § 15–847.2 OF THIS TITLE, A pharmacy 6 benefits manager may require a beneficiary to use a specific pharmacy or entity for a 7 specialty drug as defined in § 15–847 of this title.

8 15-1612.

9 (a) This section applies only to a pharmacy benefits manager that provides 10 pharmacy benefits management services on behalf of a carrier.

11 (b) This section does not apply to reimbursement:

12 (1) EXCEPT AS PROVIDED IN § 15–847.2 OF THIS TITLE, for specialty 13 drugs;

14 (2) for mail order drugs; or

15 (3) to a chain pharmacy with more than 15 stores or a pharmacist who is 16 an employee of the chain pharmacy.

17 (c) A pharmacy benefits manager may not reimburse a pharmacy or pharmacist 18 for a pharmaceutical product or pharmacist service in an amount less than the amount that 19 the pharmacy benefits manager reimburses itself or an affiliate for providing the same 20 product or service.

SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall apply to all policies, contracts, and health benefit plans issued, delivered, or renewed in the State on or after January 1, 2026.

24 SECTION 3. AND BE IT FURTHER ENACTED, That this Act shall take effect 25 January 1, 2026.